Hepatocellular carcinoma · Radiofrequency ablation · Overall survival · Two-dimensional supersonic shear-wave elastography · Liver stiffness measurement Abstract Purpose: To evaluate the prognostic value of liver stiffness (LS) measured using two-dimensional (2D) shear-wave elastography (SWE) in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation (RFA). Methods: The Institutional Review Board approved this retrospective study and informed consent was obtained from all patients. A total of 134 patients with up to 3 HCCs ≤5 cm who had undergone pre-procedural 2D-SWE prior to RFA treatment between January 2012 and December 2013 were enrolled. LS values were measured using real-time 2D-SWE before RFA on the procedural day. After a mean follow-up of 33.8 ± 9.9 months, we analyzed the overall survival after RFA using the Kaplan-Meier method and Cox proportional hazard regression model. The optimal cutoff LS value to predict overall survival was determined using the minimal p value approach. Results: During the follow-up period, 22 patients died, and the estimated 1-and 3-year overall survival rates were 96.4 and 85.8%, respectively. LS measured by 2D-SWE was found to be a significant predictive factor for overall survival after RFA of HCCs, as was the presence of extrahepatic metastases. As for the optimal cutoff LS value for the prediction of overall survival, it was determined to be 13.3 kPa. In our study, 71 patients had LS values ≥13.3 kPa, and the estimated 3-year overall survival was 76.8% compared to 96.3% in 63 patients with LS values <13.3 kPa. This difference was statistically significant (hazard ratio = 4.30 [1.26-14.7]; p = 0.020). Conclusion: LS values measured by 2D-SWE was a significant predictive factor for overall survival after RFA for HCC.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third most common cause of cancer-related death worldwide [1, 2] . Among the various treatment options available for patients with HCCs, radiofrequency ablation (RFA) has emerged as an effective local treatment option with curative intent in patients with cirrhosis and small HCCs <3 cm in diameter [2] [3] [4] . Indeed, according to several management guidelines for HCC such as those of the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD), RFA is recommended for the treatment of patients with small, early-stage HCCs and portal hypertension [2, [4] [5] [6] [7] [8] . Recently, with surveillance tests using ultrasound (US) on the rise for patients at high risk of developing HCCs such as those with cirrhosis or chronic hepatitis B viral infection, increased detection of small HCCs and a concordant increase in RFA treatment of HCCs has been documented [5, 6] .
Previous studies investigating the clinical outcome of RFA for HCCs have shown that a patient's underlying liver function can significantly affect overall survival, with many studies reporting that Child-Pugh class B liver function is a significant determinant of poor overall survival after RFA for early-stage HCCs [2, 4, 9, 10] . The presence of cirrhosis and the degree of liver fibrosis have also been shown to be negative factors for liver regeneration [11, 12] . With recent advances in US technology, various elastography techniques including transient elastography (TE) (Fibroscan; Echosense, Paris, France), point shear-wave elastography (SWE) and two-dimensional (2D)-SWE by Aixplorer ® have been confirmed to be effective tools for the staging of liver fibrosis and the diagnosis of liver cirrhosis [13] [14] [15] [16] [17] . In addition, a recent study reported that liver stiffness (LS) measurements using TE have also shown the capability to predict the 5-year survival of patients with chronic hepatitis C [18] . According to one recent study comparing the accuracies of various US elastography techniques for the staging of liver fibrosis, TE, acoustic radiation force impulse imaging, and 2D-SWE were shown to be comparably effective methods for the noninvasive assessment of liver fibrosis [16] . However, in contrast to TE, point SWE and 2D-SWE can provide real-time B-mode US imaging which can aid in the planning and guidance of interventional procedures including RFA, and LS measurements obtained through SWE can easily be linked to RFA procedures [19] . Moreover, 2D-SWE allows real-time bidimensional assessment of LS in larger regions, and therefore LS values measured by 2D-SWE can provide information regarding the degree of liver fibrosis [15, 16, 19] . We therefore hypothesized that LS values measured by 2D-SWE might be a significant predictive factor for the clinical outcome of RFA in patients with HCCs. Thus, the purpose of this study was to evaluate the value of LS measured by 2D-SWE as a predictor of the clinical outcome in HCC patients treated by RFA.
Patients and Methods

Patients
Our Institutional Review Board approved this retrospective analysis of prospectively collected pre-RFA SWE data and written informed consent was obtained from all patients. From January 2012 to December 2013, 151 patients with HCCs were treated by RFA and met the following eligibility criteria for inclusion in this study. The eligibility criteria for this study were: (a) fewer than 3 HCC nodules without extrahepatic metastasis or macrovascular invasion; (b) largest diameter of the tumor ≤5 cm; (c) well-compensated ChildPugh class A liver function; (d) prothrombin activity >40% and a platelet count >5 × 10 9 /L; (e) successfully measured LS values using 2D-SWE prior to RFA; (f) patients who underwent liver transplantation after RFA for HCC during the follow-up period; and (g) available follow-up imaging study and/or medical records to assess the clinical outcome of RFA. Of the 151 patients, 17 patients were excluded from the study due to either technical failure to obtain LS value measurements using 2D-SWE (n = 3), immediate follow-up loss after RFA (n = 3), or undergoing liver transplantation during the follow-up period (n = 11). The remaining (Fig. 1) . The baseline characteristics of the study population are summarized in Table 1 . The FIB-4 index was also calculated by using the following equation: [20] .
LS Measurements Using Supersonic Shear-Wave Imaging
LS value measurements were performed six times using a convex broadband probe (Aixplorer SC6-1; Supersonic Imagine) by one abdominal radiologist (J.M.L.) with 20 years of experience in liver US imaging on the same day just before RFA (interval between SWE and RFA: 0.5-6 h). All patients had fasted for at least 6 h prior to the examination. LS value measurements were done with the patient in the supine position with the right arm extended above the head to stretch the intercostal muscles [21, 22] . LS value measurements were performed in the right lobe of the liver through the intercostal space in order to ensure a proper sonic window and to avoid any artifacts from cardiac motion as well as HCC lesions. The convex probe was kept still for 5-7 s during acquisition, and patients were asked to hold their breath during the examination for exact acquisition. A 2 × 2 cm SWE box was placed in the liver parenchyma to avoid large vessels, and the upper edge of the SWE box was placed 1.5-2.0 cm away from the Glisson capsule. LS values were obtained within a region of interest of 10 mm 2 in diameter that most clearly displayed homogeneous stiffness within the plane but showed no movement or pressure artifacts. The mean value of LS expressed in kilopascal was used as the representative measurement in each patient ( Fig. 2) [17] . Measurements were considered to have failed when little or no signal was obtained in the SWE box after at least 6 trials [21] .
RFA Procedures and Follow-Up after Treatment
All RFA procedures were performed percutaneously under conscious sedation (fentanyl citrate [Hana Pharm, Seoul, Korea], midazolam [Hana Pharm, Seoul, Korea], and ketamine [Huons, Hwaseong, Kyunggi, Korea]). RFA was performed using the switching monopolar technique with a separable clustered electrode (Octopus electrodes; STARmed, Goyang, Kyunggi, Korea) and a 200-W multichannel generator (VIVA RF System, STARmed).
Follow-up examinations, including contrast-enhanced, multiphasic liver computed tomography (CT) or MRI, liver function tests, and measurement of serum alpha-fetoprotein levels were done in all patients 1 month after RFA. According to the 1-month follow-up imaging results, the technical success of the RFA procedure was assessed for each patient. Treatment failure was defined as (1) failure of the ablation zone to completely encompass the tumor seen on CT or MRI obtained before the RFA procedure or (2) presence of an arterial enhancing foci of tissue showing washout at portal or delayed phase images at the site of the original tumor seen on 1-month follow-up imaging [23, 24] . For these patients, other possible treatment options including hepatic resection, repeated ablation, liver transplantation, and transarterial chemoembolization (TACE) were considered. Treatment success was defined as complete ablation observed on 1-month follow-up images. In cases of treatment success, follow-up contrast-enhanced, multi-phase liver CT or MRI Fig. 2 . Measurement of liver stiffness values using supersonic shear-wave elastography in a 54-year-old male with hepatocellular carcinoma before radiofrequency ablation. Liver stiffness was measured in the right lobe of the liver on supersonic shear-wave elastography.
and measurement of the serum alpha-fetoprotein level were performed every 3 months during the first year, and then every 3-6 months during the second year [25] . Thereafter, if no tumor recurrence was observed, patients were followed up based on the schedule set for the surveillance program for liver cirrhosis.
Development of tumor recurrence during the follow-up period was evaluated and was classified into three categories: local tumor progression (LTP), intrahepatic distant recurrence (IDR), and extrahepatic metastases (EM). LTP was defined as the reappearance of enhancing tumor tissue adjacent to the ablated zone after achievement of treatment success, and IDR as the emergence of 1 or more HCCs not adjacent to the treated site [23] . The appearance of EM was also assessed on follow-up imaging. When we observed LTP, IDR, or EM on follow-up imaging, the date of each type of recurrence was recorded.
Statistical Analysis
Categorical variables were compared using the Fisher exact test and continuous variables using the Mann-Whitney test for univariate analysis; a p value <0.05 was considered to indicate statistical significance. Overall survival was defined as the interval between RFA treatment and death or the date of the last followup visit before May 31, 2016. Patients who underwent liver transplantation during the follow-up period after RFA were excluded from this study at the date of their transplantation. Recurrence-free survival was defined as the interval between RFA treatment and the first date of any type of HCC recurrence (either local and/or distant) or the last follow-up date without recurrence.
Univariate and multivariate analyses were performed to determine significant clinical and biological parameters able to predict overall and recurrence-free survival. Survival curves were estimated using the Kaplan-Meier method and a univariate Cox proportional hazards model was fitted to each variable. All variables with a p value <0.05 were included in the multivariate analysis using a stepwise Cox hazards regression model in order to evaluate their value as independent predictors. All statistical analyses were performed using SPSS version 21 (SPSS, Chicago, IL, USA). To obtain the optimal cutoff LS value for predicting overall survival after RFA, the minimal p value approach based on the log-rank test statistic was used [26] . Thereafter, for internal validation of the optimal cutoff LS value, twofold cross-validation was performed [27] . Determination of the optimal cutoff LS value measured by SWE and the internal validation was done using SAS 9.2 version (SAS Institute Inc., Cary, NC, USA) after consultation with a biostatistician working at the Medical Research Collaborating Center of our institute. All authors had access to the study data and reviewed and approved the final manuscript.
Results
LS Measurements using Supersonic Shear-Wave Imaging
Among the 151 patients who initially underwent LS measurements using 2D-SWE, measurement success was achieved in 148 patients resulting in a technical success rate of 98.0% (148/151). In addition, 14 patients in whom successful LS value measurements were obtained using 2D-SWE were excluded from this study due to the lack of follow-up imaging studies (n = 3) and undergoing liver transplantation after RFA during the follow-up period (n = 11). Mean and median LS values for the final 134 patients measured by 2D-SWE were 14.6 ± 6.05 (SD) and 13.8 kPa (standard error [SE], 0.52), respectively, and ranged from 4.4 to 42.5 kPa.
Treatment Outcome of RFA There were no procedure-related mortalities in this study. For the treatment of HCCs, a total of 141 RFA sessions were performed in 134 patients (1 session in 127 patients and 2 sessions in 7 patients). Treatment success assessed by 1-month follow-up CT or MRI obtained after RFA was achieved in 130 of 134 patients (97.0%, 130/134). Thus, treatment failure was observed in 4 of 134 patients and was retreated by repeat RFA (n = 1) and TACE (n = 3).
Survival Outcome after RFA
During a mean and median follow-up period of 33.8 ± 9.9 and 36.0 months (SE, 0.86), respectively, 22 (15.2%) patient deaths occurred due to the following causes: liver failure (n = 7); progression of HCC (n = 14); and pneumonia (n = 1). The estimated 1-and 3-year overall survival rates after RFA for HCCs in the 134 patients were 96.2 and 85.4%, respectively (Fig. 3) . We also found that LS values measured by 2D-SWE were a significant affecting factor for overall survival after RFA (p = 0.002). The optimal cutoff value was set at 13.3 kPa using the minimal p value approach, and twofold cross-validation results revealed that this cutoff LS value was internally valid (p = 0.020). Of the 63 patients with LS values less than 13.3 kPa measured by 2D-SWE, 3 patients died during the follow-up period due to the progression of HCCs, resulting in estimated overall 1-and 3-year survival rates of 98.3 and 96.3%, respectively. Among the 71 patients with LS values ≥13.3 kPa measured by 2D-SWE, 19 patients died due to liver failure (n = 7), progression of HCCs (n = 11) or pneumonia (n = 1), and the estimated overall 1-and 3-year survival rates were 94.4 and 76.8%, respectively. This difference was statistically significant (hazard ratio = 4.30, 95% confidence interval = 1.26-14.7; p = 0.020, Fig. 4) .
The prognostic factors affecting overall survival after RFA of HCCs are summarized in Table 2 . According to univariate analysis, serum albumin level >36 g/L, FIB-4 index >5.29, doing antiviral therapy, the appearance of extrahepatic metastasis and LS values ≥13.3 kPa measured by 2D-SWE were significant predictors of overall survival. However, only the appearance of extrahepatic metastasis and LS values ≥13.3 kPa measured by 2D-SWE were revealed to be significant predictive factors for overall survival at multivariate analysis. The survival outcome according to the previous history of HCC treatment and etiology of HCC were given in supplementary material. Values in italics are significant. HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; HR, hazard radio; INR, international normalized ratio; AFP, alpha-fetoprotein (per 100 units); LS, liver stiffness; SWE, supersonic shear-wave elastography. Figures in italics are significant. HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; HR, hazard radio; INR, international normalized ratio; AFP, alpha-fetoprotein (per 100 units); LS, liver stiffness; SWE, supersonic shear-wave elastography.
Discussion
According to our study results, LS measured by 2D-SWE in patients with HCCs treated by RFA was a significant predictive factor for overall survival, with the optimal cutoff LS value for the prediction of overall survival determined as 13.3 kPa (hazard ratio = 4.30, 95% confidence interval 1.26-14.7; p = 0.020). In addition, on multivariate analysis, conventional fibrosis markers calculated by using serum biochemical test such as FIB-4 index was not a significant affecting factor for overall survival after RFA for HCC, which could mean that the FIB-4 index was not enough to predict overall survival and addition of 2D-SWE might be helpful to predict patient outcome. Our study results well correlate with the results of a previous study by Vergniol et al. [18] , which also reported that LS values measured by TE were able to predict the 5-year survival of patients with chronic hepatitis C. This similarity in our study results is surprising given the significant differences between our study populations (i.e., patients with HCCs in our study vs. patients with chronic hepatitis C) and LS value measurement methods (i.e., 2D-SWE in our study vs. TE). As for the optimal cutoff value for the prediction of overall survival after RFA, our calculated value of 13.3 kPa was similar to the cutoff value of 15.4 kPa previously proposed as the optimal cutoff LS value for the diagnosis of clinically significant portal hypertension [28] . Indeed, several studies have previously reported that LS values measured by TE or 2D-SWE were moderately correlated with the hepatic vein pressure gradient (HVPG), which is considered to be the standard method of diagnosing portal hypertension [29, 30] . In addition, regarding surgical resections for patients with HCCs, the presence of portal hypertension is a well-known risk factor for both the development of posthepatectomy liver failure and overall survival outcome after treatment [31] [32] [33] . Therefore, considering these previous study results and our own, it is possible that the poor overall survival rate after RFA of HCCs in patients with higher LS values could be due to the presence of portal hypertension. In addition, increased LS value measured by 2D-SWE can indicate the presence of more advanced stage of fibrosis/ cirrhosis, and the presence of advanced stage of fibrosis/cirrhosis has been a well-known negative factor for liver regeneration. Therefore, the negative effect on liver regeneration of increased LS value measured by 2D-SWE might also explain our study result of poor overall survival outcome after RFA for HCCs in patients with increased LS value measured by 2D-SWE [11, 12] .
From a clinical point of view, the survival estimates obtained in our study may have an impact on the choice of the appropriate treatment modality in patients with HCCs. According to our study results, in patients with LS values less than 13.3 kPa determined by 2D-SWE, the estimated 3-year survival rate was 96.3%, which is comparable to that of liver transplantation. Therefore, in those patients in whom surgical resection is not possible due to concerns of posthepatectomy liver failure or other comorbidities which preclude major surgery, RFA may be the best therapeutic option. Conversely, in patients with LS values ≥13.3 kPa, the estimated 3-year survival rate was 76.8% which is significantly lower than that in patients with an LS value <13.3 kPa. Therefore, in those cases, liver transplantation would be the better choice if and when a donor's liver becomes available. However, larger studies with a prospective design are warranted to more confirmatively assess whether LS values measured by 2D-SWE could be used to determine the optimal treatment modality for HCC.
Until now, TE has been the most widely used modality to assess the degree of liver fibrosis, and its diagnostic and prognostic values have been extensively evaluated and validated [13, 14, 17, 18] . Nonetheless, 2D-SWE has several clear advantages over TE. First, the diagnostic performance of 2D-SWE in assessing the degree of liver fibrosis is more favorable than with TE [17, 34] . Second, unlike TE, the US equipment of 2D-SWE can provide real-time B-mode imaging of the liver. Therefore, US equipment of 2D-SWE can easily be used in conjunction with interventional procedures such as RFA. To the contrary, 2D-SWE might be more limited by factors such as operator variability compared to TE, as 2D-SWE embedded in a conventional scanner allows the choice of where to place the region of interest within the color stiffness box and whether to confirm or exclude each single measurement when determining the final value, while these choices are not available with TE [15] . In addition to US elastography including 2D-SWE and TE, magnetic resonance elastography (MRE) of the liver is another noninvasive method which can be used to measure the viscoelastic properties of the liver, providing a quantitative method for the diagnosis of liver fibrosis and cirrhosis as well as accurate liver fibrosis staging [35] [36] [37] [38] [39] [40] . However, although the reproducibility of MRE for liver fibrosis has been reported to be even better than that of US elastography, the cost of MRE is much higher than that of SWE [41, 42] . In addition, MRE requires a longer acquisition time, and claustrophobia and the presence of iron overload in the liver are other limitations of MRE in assessing the degree of fibrosis at present [34] .
Our study has several limitations. First, even though our cutoff LS value of 13.3 kPa for predicting overall survival after RFA of HCCs was internally validated, our study results need to be validated by other studies. It would be especially important to validate these results in Western populations, as the etiology of liver cirrhosis and HCC is different between Asian populations (i.e., hepatitis B virus infection) and Western populations (i.e., hepatitis C virus infection or alcohol related). Therefore, further studies including patients with other etiologies of liver disease are warranted for the generalization of our results. Second, as HVPG measurements were not performed prior to RFA in our study, we could not correlate the LS values measured by 2D-SWE with the presence of portal hypertension. However, according to most current guidelines, RFA is recommended for early-stage HCCs in patients with portal hypertension who cannot undergo liver transplantation mainly due to the shortage of donor livers [5] [6] [7] . In addition, a recent guideline has recommended RFA as the first-line treatment modality for very early-stage HCCs regardless of the presence of portal hypertension [7] . Therefore, HVPG measurements before RFA has generally not been recommended in the current management guidelines for HCCs.
In conclusion, LS values measured by 2D-SWE were a significant predictive factor for overall survival after RFA of HCCs.
